Alzheimer's treatment where does it occure ?

One of the most important worldwide challenges are the next generation Alzheimer's disease treatments. Alzheimer's disease treatments worldwide leaders will meet at the CTAD 2019 Congress in order to discuss new results, candidate therapeutics, and methodological issues. The CTAD Congress participants will be able to share their experience on Alzheimer's disease treatments and dementia symptoms. The CTAD 2019 Congress will provide the participants with new reports on the biomarkers from the clinical trial teams. Safe drugs represent some of the future treatment trials in order to avoid Alzheimer's disease progression. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Tau Biomarkers was proved to be one of the therapeutics combination as shown in the phase 43 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. New examples of trials will be highlighted in the 2019 CTAD Congress. Speeding the development of effective Alzheimer's treatment disease is one of the urge of the CTAD 2019 conference. The JPAD Journal of Prevention of Alzheimer's Disease will publish reviews, original research articles and short reports to improve our knowledge in the field of Alzheimer prevention including : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.